PASSAT: CRT( Chemo-Radiation Therapy) Patterns and Short-term Outcomes on Unresectable NSCLC in Routine Practices in Russia
Study Details
Study Description
Brief Summary
This is a multi-center, non-interventional, study with the aim to access routine practice of diagnostic and treatment approaches in patients with NSCLC in 50 largest oncology centers in Russian Federation. The data for all 6000 patients with LA NSCLC who receiving CRT will have been collected for 2 years from the primary medical records. Demographic and clinical characteristics of the patients, information of routine diagnostics procedures and treatment approaches for patients with unresectable LA NSCLC and the treatment results of the end of CRT will be collected. Information about any specific NSCLC treatments following CRT (e.g., durvalumab) will not be collected in the study. Patients with NSCLC meeting the inclusion criteria will be prospectively enrolled into the study. Study procedures will comply with all the local regulatory requirements regarding AE reporting (pharmacovigilance). Study design considers secondary data collection approach using existing patients' medical records, after patients' visits according to routine sites' practice. Data for visit (record) 1 will be collected at the start of CRT (concurrent or sequential), and data for visit (record) 2 will be collected after the last dose of RT and with CT control results available, but the time frame for this data collection is expected to be no later than 6 months after visit 1.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
|
Study Design
Outcome Measures
Primary Outcome Measures
- Demographic and clinical characteristics of the population. NSCLC stage by TNM classification (% of patients). Patient status - locoregional recurrence and inoperable. Histology type. % of patients with known PD-L1 status and EGFR mutation status. [Baseline]
% of patients with each TNM stage % of patient with locoregional recurrence and inoperable patients (including patient's refusal) Median age at the start of CRTs, % male/female, % of patients with comorbidities (and % by comorbidity type by MedDRA SOC/PT), % on concomitant medications, % of patients by ECOG category; % of patients with each tumour histology type; % of patients with known PD-L1 status (and of those - % positive); % of patients with known EGFR mutation status (and of those % by mutation status).
Secondary Outcome Measures
- Chemoradiotherapy (CRT) details [up to 6 month]
· % of induction chemotherapy,
- The short-term effectiveness results of the initial CRT treatment administered to patients with recently first diagnosed LA NSCLC (% of patients with CR, PR, ORR, SD, PD, unevaluable for response) for cCRT and sCRT respectively [up to 6 month]
% of patients with CR, % of patients with PR, % of patients with OR (ORR), % of patients with SD, % of patients with PD, % of patients unevaluable for response
- Patterns of routine diagnostics and treatment for patients with unresectable LA NSCLC [up to 6 month]
Frequency distribution of each diagnostic approach applied;
- Patterns of routine diagnostics and treatment for patients with unresectable LA NSCLC. [up to 6 month]
Median time between the date patient first came to oncology center and the date of examination (by each approach);
- Patterns of routine diagnostics and treatment for patients with unresectable LA NSCLC. [up to 6 month]
Median time between the date of examination and date of start of CRT (by each approach);
- Patterns of routine diagnostics and treatment for patients with unresectable LA NSCLC. [up to 6 month]
Frequency distribution of results by categories (for example, staging, size, location, etc.) for each approach.
- Chemoradiotherapy (CRT) details: concurrent CRT vs sequential CRT [up to 6 month]
Frequency distribution of patients who receive concurrent or sequential CRT
- Chemoradiotherapy (CRT) details: presence of interruptions [up to 6 month]
% of CRT interruptions
- Chemoradiotherapy (CRT) details: number of interruptions [up to 6 month]
average number of interruptions per patients
- Chemoradiotherapy (CRT) details: durations of interruptions [up to 6 month]
median interruption duration (days) (based on mean duration per patient)
- Chemoradiotherapy (CRT) details:Reasons for RT interruptions and dose reductions/ withdrawals; [up to 6 month]
frequency distribution of reasons to interrupt or stop RT
- Chemoradiotherapy (CRT) details:· RT: doses, fractionation, planning, selective and elective irradiation of lymph nodes [up to 6 month]
frequency distribution of the number of RT fractions received
- Chemoradiotherapy (CRT) details:· Type of platinum-based chemotherapy used [up to 6 month]
Frequency distribution of number chemotherapy courses, of types of platinum chemotherapy used
- Chemoradiotherapy (CRT) details: For sCRT: duration between ChT and RT [up to 6 month]
For sCRT: range and median number of chemotherapy courses, median days between chemotherapy and radiotherapy
- Chemoradiotherapy (CRT) details [up to 6 month]
· For ChT: number of chemotherapy courses
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Age ≥ 18 years old
-
Provision of written informed consent
-
Patient received at least one RT dose under prescribed CRT (concurrent or sequential) for definitive treatment of locally advanced NSCLC (stage II-III, unresectable or inoperable NSCLC, including locoregional recurrence and patient's refusal to undergo surgery) based on local MDT decision
-
Patient is currently undergoing RT (preferably no more than 10 doses)
Exclusion Criteria:
-
Participation in another clinical study with an investigational product during the last 3 months
-
Confirmation that the subject was already included in this study before
-
Absence of written informed consent form
-
Data erroneously collected from subjects for which written consent is not available, will not be included in or will be deleted from the study database.
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | GBU Republic oncology dispensary | Grozny | Russian Federation | ||
| 2 | Irkutsk Regional Cancer Center | Irkutsk | Russian Federation | ||
| 3 | Kostroma Regional Cancer Center | Kostroma | Russian Federation | ||
| 4 | Sbhi Od №2 | Sochi | Russian Federation | ||
| 5 | GBUZ "SakhOOD" | Yuzhno-Sakhalinsk | Russian Federation |
Sponsors and Collaborators
- AstraZeneca
Investigators
None specified.Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- D133HR00026